Camlin Fine Sciences Ltd
Company Profile
Business description
Camlin Fine Sciences Ltd is engaged in the research, development, manufacturing, and marketing of specialty chemicals, ingredients, and additive blends. Its broad product portfolio includes Shelf-Life Solutions, Aroma Ingredients, Performance Chemicals, and Health & Wellness. The Company operates through one reporting business segment, Specialty Chemicals. Its products include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), Tert Butylcatechol (TBC), Guaiacol, Veratrole, Xtendra, Nasure, Ezential, adorr, Vitafor, Dinamic, and Biosus. It serves Food & Beverages, Petfood and Rendering, Animal Nutrition, Petrochemicals, Nutrition & Health, Biofuel, Flavours & Fragrances, and other industries, and generates maximum revenue from the domestic market.
Contact
CST Road, Kalina
Floor 2 to 5, In GS Point
Santacruz East
MumbaiMH400 098
INDT: +91 2267001000
Sector
Basic Materials
Stock type
Cyclical
Industry
Specialty Chemicals
Fiscal Year End
31 March 2027
Employees
1,439
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
stocks
Undervalued ASX miner hits production homerun
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,561.17 | 75.53 | 0.89% |
| DAX 40 | 25,814.45 | 202.42 | 0.79% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,957.25 | 59.98 | 0.55% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |